Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Investor Investigation Over Executive Compensation Announced

If you are a current long-term stockholder of shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Raptor Pharmaceutical
Affected Securities: 
NASDAQ: RPTP

Jan. 29, 2013 (Shareholders Foundation) -- An investigation on behalf of current long term investors in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) was announced concerning whether certain officers and directors of Raptor Pharmaceutical Corp. breached their fiduciary duties by paying certain top officials at Raptor Pharmaceutical excessive compensation.

The investigation by a law firm focuses on whether certain directors and officers of Raptor Pharmaceutical Corp. harmed the company by agreeing to pay certain of Raptor Pharmaceutical’s senior officers and executives excessive compensation.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) reported that its Net Loss increased from $37.19 million for the 12 months period that ended on August 31, 2011 to $38.64 million for the 12 months period that ended on August 31, 2012.

Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded in early 2012 as high as $7.79 per share but declined in November 2012 to as low as $4.45 per share.

The compensation over certain top officials at Raptor Pharmaceutical Corp. increased between its Fiscal Year 2010 and 2011. For instance, the CEO’s total compensation increased from over $355,000 in the FY 2010 to $964,000 in the FY 2011.

On Jan 24, 2013, NASDAQ:RPTP shares closed at $5.57 per share.